Tenaya Therapeutics (TNYA) Stock: Buy, Sell, or Hold?
TNYA - Tenaya Therapeutics, Inc. Common Stock
$0.64
-0.01 (-1.36%)
▼
5d:
-7.95%
30d:
-16.18%
90d:
-11.09%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When TNYA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TNYA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TNYA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TNYA is currently trading at $0.64, which is considered oversold relative to its 30-day fair value range of $0.67 to $0.74. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.6) compared to its historical average (10.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TNYA is in a strong uptrend. The price is currently testing key support at $0.64. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TNYA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.20 (+400.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TNYA is in a strong uptrend. The price is currently testing key support at $0.64. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TNYA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.20 (+400.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.67 -
$0.74
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 400.0% below Wall St target ($3.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.67 -
$0.74
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.64
Resistance Level
$0.71
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.63
Wall Street Target
$3.20
(+400.0%)
PE vs Historical
-1.6 vs 10.3
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 1:09 PM ET
Data refreshes hourly during market hours. Next update: 2:09 PM
Data refreshes hourly during market hours. Next update: 2:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNYA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
